TRAF3IP2
E3 ubiquitin ligase TRAF3IP2
As of the edition of 20 October 2026, TRAF3IP2 (E3 ubiquitin ligase TRAF3IP2, UniProt O43734) has 1 drug tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O43734
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 1
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Eye; Mouth and teeth; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Iguratimod | Marketed | Phase 4 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 2 |
| Total on the list | 2 |